Cure8

Why This Matters

Circulating glycoprotein signals may help explain how systemic inflammation in IBD interacts with metabolic liver disease (MASLD). If validated, they could improve risk stratification for liver complications beyond current non‑invasive tests.

Who Should Pay Attention

Clinicians and researchers working at the intersection of IBD and liver disease, hepatology and gastroenterology investigators, and patients with IBD who have metabolic risk factors or suspected fatty liver.

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

This abstract reports a study that measured plasma Glyc-A, Glyc-B and Glyc-F by NMR in people with IBD, with and without MASLD, and matched controls. Glycoprotein concentrations increased from controls to IBD and were highest when IBD and MASLD coexisted; Glyc-B and Glyc-F remained associated with MASLD after adjustment for metabolic variables.

The authors emphasise these findings are biologically interesting but not ready for clinical use.

The signals are composite and influenced by acute-phase proteins, systemic inflammation, adiposity, insulin resistance, dyslipidaemia and liver injury; further work is needed to link them to specific liver outcomes (especially fibrosis) and to show added value beyond existing non-invasive tests.

Keep In Mind

The source is an abstract in Revista espanola de enfermedades digestivas; the authors caution that glycoprotein NMR signals are composite markers influenced by multiple processes and that current evidence supports biological plausibility but not routine clinical use.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationRevista espanola de enfermedades digestivas
AuthorsJavier Crespo, Paula Iruzubieta
InstitutionDigestive Diseases, Hospital Universitario Marqués de Valdecilla, 39002.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 30, 2026, 12:00 AM
Content availableJournal abstract

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →